Press Room - Sanofi US News
WEB5 days ago · Sanofi continues to advance SARCLISA as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications.
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Release: Sarclisa approved in the US as the first anti ... - Sanofi
WEB4 days ago · Brian Foard Executive Vice President, Head of Specialty Care, Sanofi “Since first launching in 2020, we have made significant progress towards our ambition of establishing Sarclisa as a best-in-class therapy. The FDA’s decision marks another momentous milestone toward our goal and expands the reach of this potentially transformative therapy ...
Press Release: Sarclisa accepted for FDA priority review for ... - Sanofi
WEBMay 27, 2005 · Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma. FDA Priority Review granted based on positive results from IMROZ phase 3 study. If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care …
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of ... - Sanofi
WEBDec 7, 2006 · The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy.
Press Release: Sarclisa approved in the US as the first anti
WEB4 days ago · Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six ...
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple …
WEB1 day ago · On Saturday, the FDA approved Sanofi’s SA (NASDAQ:SNY) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult ...
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple …
WEB1 day ago · Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...
Sanofi's Sarclisa gets one up on rival Darzalex in myeloma
WEB1 day ago · Sarclisa made around $413 million in sales for Sanofi last year, a fraction of the $9.7 billion booked by J&J for Darzalex, so having a niche free of competition from its rival could translate to ...
- Some results have been removed
Skip to content